The result of this systematic review indicated that while HCPs (Healthcare Professionals) believed that medical cannabis is a viable useful therapeutic option for patients, they do not have enough knowledge and formal education to make the best decision for their patients. Consequently, they reject to prescribe or support patients to use medical cannabis or they get the information from unreliable sources such as media/news. The result of this systematic review highlights the importance of education for HCPs to ensure to offer the best possible care for patients.
The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study
Loss of appetite and weight among cancer patients are among the most challenging symptoms to be managed by physicians. Moreover, there are not effective appetite stimulant medications in the market and physicians are reluctant to add another medication to highly medicated (chemotherapeutic agents, painkillers, sleep medications, …) advanced cancer patients if they have any doubt about its efficacy or safety profile.
Cannabis has been very well-known for its appetite stimulant effect and pharmaceutical preparations such as Dronabinol were successfully tested for improving appetite in HIV patients.
In this study, Dr. Bar-Sela and his colleagues assessed the effect of Cannabis capsules (THC: CBD 20:1 ratio) for the first time among patients with advanced cancer. The planned starting dose was 20 mg of cannabinoids (19 mg THC, 1 mg CBD) per day for six months, however, if patients could not tolerate it, the dose was reduced to 10 mg per day. In total, 24 patients were enrolled for the trial, however, only 6 of them received the capsules for more than 6 months.